NCT05465941View on ClinicalTrials.gov

PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

September 14, 2022

Primary Completion Date

May 15, 2027

Study Completion Date

December 31, 2031

Conditions
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaStage IV Fallopian Tube Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8Stage IV Primary Peritoneal Cancer AJCC v8
Interventions
PROCEDURE

Biopsy

Undergo biopsy

DRUG

Pegylated SN-38 Conjugate PLX038

Given IV

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Biospecimen Collection

Undergo blood and stool sample collection

Trial Locations (1)

55905

RECRUITING

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER